Efficacy and safety of α-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy
Efficacy and safety of α-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy
复制标题
DOI：
10.1177/0145721706297450
复制
发表时间：
2007-01-01
影响因子：
3.9
通讯作者：
Foster, Tricia Stewart
中科院分区：
文献类型：
--
作者：
Foster, Tricia Stewart
目的本文旨在回顾α -硫辛酸（ALA）及其改善糖尿病周围神经病变（PDN）症状的现有证据。方法本文检索了1966年至2005年11月的MEDLINE，以确定对伴有PDN阳性感觉症状的1型或2型糖尿病患者补充ALA的临床试验。纳入本综述的临床试验符合随机化、双掩蔽和安慰剂对照设计的特定标准。结果检索结果中有5个临床试验符合本综述的先决条件。在3周的时间内通过肠外补充ALA似乎可以改善神经性症状和缺陷。口服ALA治疗是否能改善感觉症状或仅仅是单纯的神经性缺陷似乎有更多矛盾的数据。ALA的口服治疗方案和最佳治疗时间尚不清楚。静脉注射和长达2年的口服补充ALA似乎都是安全的，不会影响血糖控制。结论基于这些结果，ALA可作为PDN患者的一种治疗选择。当与患者讨论补充时，讨论潜在的副作用是很重要的；维生素、矿物质和药物的相互作用；目前关于疗效的证据。
PURPOSEThe purpose of this article is to review current evidence available for alpha-lipoic acid (ALA) and its ability to improve symptoms of peripheral diabetic neuropathy (PDN).METHODSThis article searched MEDLINE from 1966 to November 2005 to identify clinical trials that supplemented ALA to individuals with type I or type 2 diabetes and positive sensory symptoms of PDN. Clinical trials to be included in this review met specific criteria of randomization, double masking, and placebo-controlled design.RESULTSThe search results produced 5 clinical trials that met the prerequisites for this review. ALA appears to improve neuropathic symptoms and deficits when administered via parenteral supplementation over a 3-week period. Oral treatment with ALA appears to have more conflicting data whether it improves sensory symptoms or just neuropathic deficits alone. An oral regimen of ALA and optimal length of treatment remains unclear. Both parenteral and up to a 2-year time period of oral supplementation of ALA appears to be safe without affecting glycemic control.CONCLUSIONSBased on these results, ALA should be considered as a treatment option for patients with PDN. When discussing supplementation with patients, it is important to discuss potential side effects; vitamin, mineral, and drug interactions; and current evidence available regarding efficacy.